Who is sponsoring NCT00656240?

NCT00656240 is sponsored by Santen Pharmaceutical Co., Ltd..

What drugs are being tested in NCT00656240?

Interventions in NCT00656240: DE-104 ophthalmic solution, DE-104 vehicle.

What condition does NCT00656240 study?

NCT00656240 studies Open-Angle Glaucoma, Ocular Hypertension.

Is NCT00656240 still recruiting?

NCT00656240 is currently completed. Last updated 12 March 2009.

Last reviewed 2009-03-12 · How we verify

NCT00656240

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Masked, Parallel-Group Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed Phase 2 Last updated 12 March 2009

What this trial tests

Phase 2 trial testing DE-104 ophthalmic solution in Open-Angle Glaucoma. Completed.

Quick facts

Lead sponsor	Santen Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Sites	1 location across Japan

Drugs / interventions tested

DE-104 ophthalmic solution — full drug profile →
DE-104 vehicle — full drug profile →

Conditions studied

Open-Angle Glaucoma — all drugs for Open-Angle Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Santen Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 20 to 74, any sex, with Open-Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the intraocular pressure (IOP)-lowering effect and safety of DE-104 ophthalmic solution in patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Open-Angle Glaucoma

Currently open trials in the same condition.

NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07081347 — This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MIN · NA · active not recruiting
NCT06953349 — Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis · recruiting

Other Santen Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06911216 — A Pharmacokinetics (PK) Study in Healthy Adults · EARLY_PHASE1 · completed
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT05905653 — Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers · Phase 1 · completed
NCT05495061 — A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension · Phase 3 · completed
NCT05503901 — A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00656240 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Santen Pharmaceutical Co., Ltd.
Last refreshed: 12 March 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00656240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing